Status:
TERMINATED
A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Posterior Blepharoconjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers. Anothe...
Eligibility Criteria
Inclusion
- Have a current diagnosis of posterior blepharoconjunctivitis in both eyes
- (except for healthy volunteers)
- Have a Best Corrected Visual Acuity (BCVA), using corrective lenses if necessary, in both eyes of at least +0.7 LogMAR
- If female, are non-pregnant or non-lactating
Exclusion
- Have anterior blepharitis
- Have lid structural abnormalities
- Have had penetrating intraocular surgery in the past 90 days or require
- penetrating intraocular surgery during the study
- Unable to withhold the use of contact lenses within 3 days prior to Visit 1
- during the study
- Have been diagnosed with ongoing glaucoma
- Have a serious medical condition which could confound study assessments
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01220258
Start Date
November 1 2010
End Date
August 1 2011
Last Update
December 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor Eye Clinic, Alkek Eye Center of Baylor College of Medicine
Houston, Texas, United States, 77030